Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Lilly Seeking Up to $300 Million for China Rights to Off-Patent Medications

publication date: Nov 19, 2018

Eli Lilly may sell China rights to a portfolio of older, off-patent antibiotics and CNS treatments in a deal that could bring between $200 and $300 million, industry sources said. No specific drugs were named, and media reports did not disclose how many drugs might be included. Lilly wants to emphasize higher margin products, especially cancer drugs, and the company has been selling assets to raise cash that will be allocated to fund its new priorities. More details....

Stock Symbol: (NYSE: LLY)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.